Join Now - it is FREE

Basic level includes our interactive biotech chatroom, forum, biotech stock screener; you also receive the biotech digest in your email everyday.

Histogenics ($HSGX) stock jumped over 54% in its pre-market session. The stock responded to the news of positive data from Phase 1 & 2 studies assessing lead product candidate NeoCart for the repair of articular cartilage injuries in the knee.
The tests were conducted on 29 patients and 21 of the patients were evaluable at the final time point of the 60-month follow-up period. The results were published in the online version of the American Journal of Sports Medicine.
The treatment is currently in Phase 3 development for the first-line treatment of full thickness knee cartilage defects in adults.

Biocept Inc. ($BIOC) announced its new in-network provider agreement with Blue Cross Blue Shield of Texas, which is the largest health benefits provider in the state. Biocept develops and provides clinically actionable liquid biopsy tests designed to improve the outcomes of cancer patients.
The agreement will help the company in further promoting its liquid biopsy approach. Michael Nall, President and Chief Executive Officer of Biocept said that new partnership may help increasing physician’s access to the non-invasive technology for their patients.
The company gained close to 250% in the past five days. However, it is still halfway away from its 52 weeks high of $5.64, offering solid upside potential to the investors.

 

• Boston Scientific ($BSX) announced that It expects to launch its Lotus Edge heart valve in the U.S. in 2018. The company reported that it has identified a non-safety problem with the valve in Europe but also has found a fix.
• AbbVie ($ABBV) announced that it will keep the drug price hike below 10% mark this year. Novo Nordisk ($NVO) earlier had made the similar announcement.

• Merck ($MRK) announced that the FDA has accepted its supplemental Biologics License Application (sBLA) for review. The application seeks approval for the use of Keytruda (pembrolizumab) plus chemo (pemetrexed plus carboplatin) for the first-line treatment of metastatic/advanced non-squamous non-small lung cancer regardless of PD-L1 expression and with no EGFR or ALK genomic tumor aberrations.
• Pluristem Therapeutics ($PSTI) announced completing the enrolment of 172 subjects in a Phase 2 clinical trial evaluating its PLX-PAD cells for the treatment of a type of peripheral artery diseased (PAD) called intermittent claudication. The data will be used to support a U.S. marketing application for another type of PAD called critical limb ischemia. A Phase 3 study will commence shortly.

 
• Derma Sciences ($DSCI) announced buying the MEDIHONEY brand and related assets from Comvita Ltd. The deal is estimated to be worth $13.25 million in cash and up to $5.00M in a potential earn-out based on the achievement of certain sales milestones.
• Vertex Pharmaceuticals ($VRTX) announced a new collaboration and license agreement with Merck KGaA ($MKGAF) covering four oncology R&D programs.

 
• NOVADAQ Technologies ($NVDQ) reported that it expects the fourth quarter revenue to be at $20.2 million while its full financial year will likely be $80.2 million, lagging behind the consensus estimates of $25.4 million and $85.3 million respectively.
• Stryker ($SYK) provided preliminary estimates for its fourth quarter revenue at $3.2 billion. Its estimate for the full financial year revenue stands at $11.3 billion.

• Keryx Biopharmaceuticals ($KERX) receives rating upgrade from Citigroup. The stock is now rated Neutral, up from buy. It’s price target has been set at $6.50 apiece.
• Intuitive Surgical ($ISRG) received Neutral rating from BTIG Research.

Gainers (% price change) Last Trade Change Mkt Cap
Derma Sciences Inc
DSCI (NASDAQ)
6.95 +1.95 (39.00%) 196.47M
Community Health Systems
CYH (NYSE)
6.81 +0.46 (7.24%) 780.39M
EXACT Sciences Corp.
EXAS (NASDAQ)
18.66 +1.09 (6.20%) 1.98B
Accuray Incorporated
ARAY (NASDAQ)
5.30 +0.25 (4.95%) 437.31M
Brookdale Senior Living
BKD (NYSE)
15.46 +0.67 (4.53%) 3.31B
Losers (% price change)
Myriad Genetics, Inc.
MYGN (NASDAQ)
16.12 -1.36 (-7.78%) 1.09B
Alnylam Pharmaceuticals
ALNY (NASDAQ)
41.25 -3.46 (-7.74%) 3.64B
ZIOPHARM Oncology Inc.
ZIOP (NASDAQ)
5.41 -0.42 (-7.20%) 722.59M
Zogenix, Inc.
ZGNX (NASDAQ)
11.85 -0.90 (-7.06%) 293.77M
Alkermes Plc
ALKS (NASDAQ)
54.60 -3.89 (-6.65%) 8.10B
Most Actives (dollar volume)
Merck & Co., Inc.
MRK (NYSE)
61.63 +1.71 (2.85%) 166.64B
Pfizer Inc.
PFE (NYSE)
32.83 -0.60 (-1.79%) 199.05B
Bristol-Myers Squibb Co
BMY (NYSE)
56.80 -3.19 (-5.32%) 95.32B
Gilead Sciences, Inc.
GILD (NASDAQ)
73.77 -1.24 (-1.65%) 96.13B
Johnson & Johnson
JNJ (NYSE)
114.73 -1.44 (-1.24%) 311.80B